Results 181 to 190 of about 22,631 (237)
Sneddon's Syndrome and Antithrombin III
The Journal of Dermatology, 1999 AbstractSneddon's syndrome, an uncommon disorder, is characterized by multiple cerebrovascular accidents along with ideopathic livedo reticularis. In this article, two cases who had increased amounts of antithrombin III and were diagnosed with Sneddon's syndrome are presented.
Bolayir E. +4 more
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Congenital antithrombin III deficient neonate treated with antithrombin III concentrates
Thrombosis Research, 1993A patient with antithrombin III deficiency developed deep vein thrombosis during her first pregnancy. Her pregnancy and delivery were successfully treated with simultaneous administration of antithrombin III concentrates and low molecular weight heparin. She delivered a 2,412g girl at 39 weeks' gestation. The baby was administered with antithrombin III
A Shiozaki +2 more
exaly +3 more sources
Thrombosis Research, 1987
Antithrombin III (AT III) microheterogeneity was investigated in 12 cases of congenital AT III deficiency and 2 cases of congenital AT III abnormality by isoelectric focusing (IEF) and immunofixation. In congenital AT III deficiency, IEF and immunofixation revealed AT III as 8 bands which was indistinguishable from normal control in terms of the number
N, Sakuragawa +4 more
openaire +2 more sources
Antithrombin III (AT III) microheterogeneity was investigated in 12 cases of congenital AT III deficiency and 2 cases of congenital AT III abnormality by isoelectric focusing (IEF) and immunofixation. In congenital AT III deficiency, IEF and immunofixation revealed AT III as 8 bands which was indistinguishable from normal control in terms of the number
N, Sakuragawa +4 more
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1978
To the Editor.— In a recent letter to the editor, Rodger L. Bick, MD, commented on methods of assay of antithrombin III (239:296, 1978), pointing out several drawbacks to the use of synthetic chromogenic substrates in such assays. His comments were prompted by an article in MEDICAL NEWS (238:1005, 1977) in which we reported that these peptides were ...
H L, Messmore, J, Fareed
openaire +2 more sources
To the Editor.— In a recent letter to the editor, Rodger L. Bick, MD, commented on methods of assay of antithrombin III (239:296, 1978), pointing out several drawbacks to the use of synthetic chromogenic substrates in such assays. His comments were prompted by an article in MEDICAL NEWS (238:1005, 1977) in which we reported that these peptides were ...
H L, Messmore, J, Fareed
openaire +2 more sources
Scandinavian Journal of Urology and Nephrology, 1979
Antithrombin III (AT-III) was measured immunologically in 20 uremic patients on maintenance hemodialysis and in 10 non-dialysed uremic patients. The dialysed patients had slightly elevated AT-III levels. The non-dialysed patients had significantly elevated AT-III levels.
K A, Jørgensen, E, Stoffersen
openaire +2 more sources
Antithrombin III (AT-III) was measured immunologically in 20 uremic patients on maintenance hemodialysis and in 10 non-dialysed uremic patients. The dialysed patients had slightly elevated AT-III levels. The non-dialysed patients had significantly elevated AT-III levels.
K A, Jørgensen, E, Stoffersen
openaire +2 more sources
A new familial variant of antithrombin III: ‘Antithrombin III Paris’
British Journal of Haematology, 1982Summary. A 59‐year‐old woman presented a recurrent history of thromboembolism. A qualitative defect of antithrombin III (AT III) was suggested by the discrepancy between a normal amount of AT III antigen and a decreased heparin cofactor activity. Six members of the same family showed a similar defect although clinically asymptomatic.
M, Wolf +3 more
openaire +2 more sources
Antithrombin III I. Evaluation of an automated antithrombin III method
Thrombosis Research, 1978Abstract An automated method for the determination of antithrombin III activity (as heparin cofactor activity) is described using the chromogenic substrate Chromozym® TH. A linear relationship is obtained between 10–160% of the AT-III activity of normal plasma and there are good correlations with both antigen level as well as with progressive ...
L H, Kahlé +3 more
openaire +2 more sources
Thrombin-Antithrombin III Complexes and Antithrombin III in Amniotic Fluid
Gynecologic and Obstetric Investigation, 2010We measured thrombin-antithrombin III (TAT) complexes and antithrombin III (AT III) in amniotic fluid and blood plasma of 39 parturient women. TAT was measured by ELISA. Partigen plates were used for measuring the antigen of AT III, and activity was determined using chromogenic substrate.
M, Uszyński +3 more
openaire +2 more sources
Safety of virus inactivated antithrombin III concentrate ANTITHROMBIN III IMMUNO (AT III)
Thrombosis Research, 1992In a prospective clinical trial the risk of infection after application of virus inactivated antithrombin III concentrate ANTITHROMBIN III IMMUNO (AT III) was investigated in patients undergoing cardiovascular surgery. The study was conducted according to the recommendations of the International Committee on Thrombosis and Hemostasis (ICTH), with the ...
D U, Preiss +3 more
openaire +2 more sources
Antithrombin III and Atherosclerosis
1984The mechanisms leading to the initiation of atherosclerosis are very complex. Since Duguid’s modification of Rokitansky’s theory, atherosclerosis has been related to thrombogenesis. Several investigators proposed the clumping of platelets to play a crucial role in the initiation of atheroma formation.
J, Conard, M, Castel, M, Samama
openaire +2 more sources